945389-41-3

Usage

Uses

Used in Pharmaceutical Industry:
2-(1,2,3,4-Tetrahydronaphthalen-1-yl)-1H-imidazole is used as a pharmaceutical agent for the treatment of various conditions, particularly those related to the α1A adrenoceptor. Its selective agonist properties make it a promising candidate for developing targeted therapies with fewer side effects.
Used in Research Applications:
In the field of scientific research, 2-(1,2,3,4-Tetrahydronaphthalen-1-yl)-1H-imidazole serves as a valuable tool for studying the role and function of the α1A adrenoceptor. It can be utilized in experiments to investigate the mechanisms of action and potential therapeutic applications related to this receptor.

Upstream product

• 84-22-0 tetrahydrozoline 

Relevant academic research and scientific papers

Novel 2-imidazoles as potent and selective α1A adrenoceptor partial agonists

Novel 2-imidazoles have been identified as potent partial agonists of the α1A adrenergic receptor, with good selectivity over the α1B, α1D and α2A receptor sub-types. Sulfonamide 23 possessed attractive drug-like properties with respect to physicochemical and ADME properties and wide ligand selectivity.

USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS

The present invention relates to the use of compounds of formula (I) R1 is hydrogen, tritium, hydroxy, lower alkyl, lower alkoxy, halogen, nitro, amino or lower alkyl substituted by halogen; R2 is hydrogen, hydroxy or lower alkyl; X is N and Y is CH or CH2 or CH-lower alkyl or X is CH and Y is N; Q is CH2, O, NH, N-alkyl or N-SO2-alkyl or N-SO2-toluen-4-yl; W is CH2 or a bond are independently from one another 1, 2 or 3; when m is 2 or 3, R2 may m, n be the same or not; when n is 2 or 3, R1 may be the same or not; the dotted lines may each be independently from one another a bond or not; and to their pharmaceutically active salts, racemic mixtures, enantiomers, optical isomers and tautomeric forms of compounds of formula (I) for the preparation of medicaments for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.